Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib-based biomarker-selected perioperative study in resectable ALK-positive non-small cell lung cancer
CTR20243865Phase 3Terminated
- Sponsor
- Roche
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of alectinib in non-small cell lung cancer (NSCLC), Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Roche. Started Oct 2024; status: terminated.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on CTR20243865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243865.